Chudi Ndubaku

Chudi Ndubaku

Auto-generated profile, based on publicly available information

Chudi Ndubaku

Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Cell Reports
Verified
Journal Article
Open access
KSKelsey E. Sivick
Kelsey E. Sivick
ADAnthony L. Desbien
Anthony L. Desbien
LGLaura Hix Glickman
Laura Hix Glickman
GRGabrielle L. Reiner
Gabrielle L. Reiner
LCLeticia Corrales
Leticia Corrales
SMSarah M. McWhirter
Sarah M. McWhirter
Intratumoral (IT) STING activation results in tumor regression in preclinical models, yet factors dictating the balance between innate and adaptive anti-tumor immunity are unclear. Here, clinical candidate STING agonist ADU-S100 (S100) is used in an IT dosing regimen optimized for adaptive immunity to uncover requirements for a T cell-driven response compatible with checkpoint inhibitors (CPIs). In contrast to high-dose tumor ablative regimens that result in systemic S100 distribution, low-dose immunogenic regimens induce local activation of tumor-specific CD8+ effector T cells that are responsible for durable anti-tumor immunity and can be enhanced with CPIs. Both hematopoietic cell STING expression and signaling through IFNAR are required for tumor-specific T cell activation, and in the context of optimized T cell responses, TNFα is dispensable for tumor control. In a poorly immunogenic model, S100 combined with CPIs generates a survival benefit and durable protection. These results provide fundamental mechanistic insights into STING-induced anti-tumor immunity.

18 October 2017 in Nature
Verified
Journal Article
Closed access
PDF file
LKLorna Kategaya
Lorna Kategaya
PLPaola Di Lello
Paola Di Lello
LRLionel Rougé
Lionel Rougé
RPRichard Pastor
Richard Pastor
KCKevin R. Clark
Kevin R. Clark
IWIngrid E. Wertz
Ingrid E. Wertz

8 September 2014 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ZTZhi-Fu Tao
Zhi-Fu Tao
LHLisa Hasvold
Lisa Hasvold
LWLe Wang
Le Wang
XWXilu Wang
Xilu Wang
APAndrew M. Petros
Andrew M. Petros
ASAndrew J. Souers
Andrew J. Souers

20 March 2020 in Science Immunology
Verified
Journal Article
Closed access
PDF file
CNChristopher J. Nicolai
Christopher J. Nicolai
NWNatalie Wolf
Natalie Wolf
ICI-Chang Chang
I-Chang Chang
GKGeorgia Kirn
Georgia Kirn
AMAssaf Marcus
Assaf Marcus
DRDavid H. Raulet
David H. Raulet
STING agonists trigger NK cell–mediated clearance of MHC-deficient tumors resistant to CD8 + T cells and NK-sensitive, MHC-expressing tumors.

3 June 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CNChudi O. Ndubaku
Chudi O. Ndubaku
THTimothy P. Heffron
Timothy P. Heffron
SSSteven T. Staben
Steven T. Staben
MBMatthew Baumgardner
Matthew Baumgardner
NBNicole Blaquiere
Nicole Blaquiere
AOAlan G. Olivero
Alan G. Olivero

18 March 2015 in Nature
Verified
Journal Article
Closed access
PDF file
PVPhilip Vitorino
Philip Vitorino
SYStacey Yeung
Stacey Yeung
ACAiley Crow
Ailey Crow
JBJesse Bakke
Jesse Bakke
TSTanya Smyczek
Tanya Smyczek
WYWeilan Ye
Weilan Ye